VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

​

​

 

 

 

Aiming to submit NDA in 2020-2021.

VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.

​

​

 

 

 

Aiming to submit NDA in 2020-2021.

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

VTS-K: Ketamine + VTS Aspirin for Postoperative Pain

Vitalis
  • About Us

  • VTS-Platform

  • What is Flush?

  • Pipeline

    • Multiple Sclerosis
    • Post-op Pain
    • Dyslipidemia
  • Media

  • Contact Us

  • More

    Use tab to navigate through the menu items.

    Media

    News
    Press Releases
    Events

    ER Doctor Aims for Patient Centered Breakthrough: A Ketamine That Works Orally

    Ketamine News

    January 28, 2021

    VTS-Aspirin Wins Orphan Status in Combination With Fumarates for Flush in MS

    NeurologyLive

    April 28, 2020

    Novel Aspirin Formulation May Address Bothersome MS Symptoms, Treatment Side Effects

    NeurologyLive

    January 10, 2020

    Vitalis Announces Plans for Low-Flush Formulation Fumarate VTS-72 In Multiple Sclerosis

    NeurologyLive

    October 24, 2019

    Potential RRMS Fumarate Treatment Free of ‘Flush’ Effect to Enter Trial in 2020, Vitalis Says

    MS News Today

    October 24, 2019

    BioWorld Today - October 23, 2019: Other news to note

    BioWorld

    subscription required to view full article

    October 23, 2019

    A new company enters the Tecfidera fight, offering to kill two birds

    ENDPOINTSNEWS

    October 22, 2019

    Vitalis Plans to Launch Phase 3 Trial Testing VTS-72 as Treatment for RRMS-related Flushing

    MS News Today

    January 10, 2020

    VTS-Aspirin Combos to Ease Flush in RRMS Named Orphan Drug by FDA

    MS News Today

    April 23, 2020

    H. C. Wainwright 22nd Annual Global Investment Conference

    Wall Street Webcasting

    September 16, 2020

    Pilot Study Launched of Ketamine Tablet as Pain Reliever

    Pain News Network

    January 20, 2021

    © 2019 Vitalis, LLC

    All Rights Reserved.

    New York, NY

    admin@vitalispharma.com

     

    ​

    Cookie Policy

    Terms of Use

    Privacy Policy

    Media